Always consult with a healthcare professional before starting any new supplement regimen, especially if you have underlying health conditions or concerns
In the SUSTAIN program, 83 patients (1.4%) treated with semaglutide developed a gallbladder event, compared with 39 patients (1.9%) in the placebo group ( versus 0.1% with placebo), while the risk of cholecystitis was similar (data derived from the summary of product characteristics (SmPC) (87), as the manuscripts did not describe these data)
Cardiometabolic markers including HbA1c, fasting glucose, blood pressure, cholesterol and triglycerides improved during treatment but are estimated to return to baseline levels within approximately 1.4 years after medicines stopped
A. V. Arutjunyan, I. G. Popovich, L. S. Kozina, and G. A. Ryzhak, Peptide Regulation of Ageing: From Experiment to Practice, Bentham Science Publishers Ltd., Feb. 2025. doi: 10.2174/0118746098346230250116065407
cofounded ConfometRx